Cargando…
Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study
The real-world effectiveness of the coronavirus disease 2019 (COVID-19) vaccines in Japan remains unclear. This case–control study evaluated the vaccine effectiveness (VE) of two doses of mRNA vaccine, BNT162b2 or mRNA-1273, against the delta (B.1.617.2) variant in the Japanese general population in...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145554/ https://www.ncbi.nlm.nih.gov/pubmed/35632535 http://dx.doi.org/10.3390/vaccines10050779 |
_version_ | 1784716344034328576 |
---|---|
author | Hara, Megumi Furue, Takeki Fukuoka, Mami Iwanaga, Kentaro Matsuishi, Eijo Miike, Toru Sakamoto, Yuichiro Mukai, Naoko Kinugasa, Yuki Shigyo, Mutsumi Sonoda, Noriko Tanaka, Masato Arase, Yasuko Tanaka, Yosuke Nakashima, Hitoshi Irie, Shin Hirota, Yoshio |
author_facet | Hara, Megumi Furue, Takeki Fukuoka, Mami Iwanaga, Kentaro Matsuishi, Eijo Miike, Toru Sakamoto, Yuichiro Mukai, Naoko Kinugasa, Yuki Shigyo, Mutsumi Sonoda, Noriko Tanaka, Masato Arase, Yasuko Tanaka, Yosuke Nakashima, Hitoshi Irie, Shin Hirota, Yoshio |
author_sort | Hara, Megumi |
collection | PubMed |
description | The real-world effectiveness of the coronavirus disease 2019 (COVID-19) vaccines in Japan remains unclear. This case–control study evaluated the vaccine effectiveness (VE) of two doses of mRNA vaccine, BNT162b2 or mRNA-1273, against the delta (B.1.617.2) variant in the Japanese general population in the period June–September 2021. Individuals in close contact with COVID-19 patients were tested using polymerase chain reaction (PCR). A self-administered questionnaire evaluated vaccination status, demographic data, underlying medical conditions, lifestyle, personal protective health behaviors, and living environment. Two vaccine doses were reported by 11.6% of cases (n = 389) and 35.2% of controls (n = 179). Compared with controls, cases were younger and had a lower proportion who always performed handwashing for ≥20 s, a higher proportion of alcohol consumers, and a lower proportion of individuals living in single-family homes or with commuting family members. After adjusting for these confounding factors and day of PCR testing by multivariate logistic regression analysis, the VE in the period June–July (delta variant proportion 45%) was 92% and 79% in the period August–September (delta variant proportion 89%). The adjusted VE for homestay, hotel-based isolation and quarantine, and hospitalization was 78%, 77%, and 97%, respectively. Despite declining slightly, VE against hospitalization remained robust for ~3 months after the second dose. Vaccination policymaking will require longer-term monitoring of VE against new variants. |
format | Online Article Text |
id | pubmed-9145554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91455542022-05-29 Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study Hara, Megumi Furue, Takeki Fukuoka, Mami Iwanaga, Kentaro Matsuishi, Eijo Miike, Toru Sakamoto, Yuichiro Mukai, Naoko Kinugasa, Yuki Shigyo, Mutsumi Sonoda, Noriko Tanaka, Masato Arase, Yasuko Tanaka, Yosuke Nakashima, Hitoshi Irie, Shin Hirota, Yoshio Vaccines (Basel) Article The real-world effectiveness of the coronavirus disease 2019 (COVID-19) vaccines in Japan remains unclear. This case–control study evaluated the vaccine effectiveness (VE) of two doses of mRNA vaccine, BNT162b2 or mRNA-1273, against the delta (B.1.617.2) variant in the Japanese general population in the period June–September 2021. Individuals in close contact with COVID-19 patients were tested using polymerase chain reaction (PCR). A self-administered questionnaire evaluated vaccination status, demographic data, underlying medical conditions, lifestyle, personal protective health behaviors, and living environment. Two vaccine doses were reported by 11.6% of cases (n = 389) and 35.2% of controls (n = 179). Compared with controls, cases were younger and had a lower proportion who always performed handwashing for ≥20 s, a higher proportion of alcohol consumers, and a lower proportion of individuals living in single-family homes or with commuting family members. After adjusting for these confounding factors and day of PCR testing by multivariate logistic regression analysis, the VE in the period June–July (delta variant proportion 45%) was 92% and 79% in the period August–September (delta variant proportion 89%). The adjusted VE for homestay, hotel-based isolation and quarantine, and hospitalization was 78%, 77%, and 97%, respectively. Despite declining slightly, VE against hospitalization remained robust for ~3 months after the second dose. Vaccination policymaking will require longer-term monitoring of VE against new variants. MDPI 2022-05-14 /pmc/articles/PMC9145554/ /pubmed/35632535 http://dx.doi.org/10.3390/vaccines10050779 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hara, Megumi Furue, Takeki Fukuoka, Mami Iwanaga, Kentaro Matsuishi, Eijo Miike, Toru Sakamoto, Yuichiro Mukai, Naoko Kinugasa, Yuki Shigyo, Mutsumi Sonoda, Noriko Tanaka, Masato Arase, Yasuko Tanaka, Yosuke Nakashima, Hitoshi Irie, Shin Hirota, Yoshio Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study |
title | Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study |
title_full | Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study |
title_fullStr | Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study |
title_full_unstemmed | Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study |
title_short | Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study |
title_sort | real-world effectiveness of the mrna covid-19 vaccines in japan: a case–control study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145554/ https://www.ncbi.nlm.nih.gov/pubmed/35632535 http://dx.doi.org/10.3390/vaccines10050779 |
work_keys_str_mv | AT haramegumi realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT furuetakeki realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT fukuokamami realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT iwanagakentaro realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT matsuishieijo realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT miiketoru realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT sakamotoyuichiro realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT mukainaoko realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT kinugasayuki realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT shigyomutsumi realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT sonodanoriko realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT tanakamasato realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT araseyasuko realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT tanakayosuke realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT nakashimahitoshi realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT irieshin realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy AT hirotayoshio realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy |